3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year
3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year
It's been a mediocre week for 3SBio Inc. (HKG:1530) shareholders, with the stock dropping 12% to HK$5.73 in the week since its latest half-year results. 3SBio reported CN¥4.4b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of CN¥0.45 beat expectations, being 2.3% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
對於3sBio Inc.(HKG: 1530)的股東來說,這是平庸的一週,該股自公佈最新的半年業績以來本週下跌了12%,至5.73港元。3sBio公佈的收入爲44元人民幣,與分析師的預測大致一致,儘管法定每股收益(EPS)爲0.45元人民幣,比分析師的預期高出2.3%。分析師通常會在每份收益報告中更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否發生了變化,或者是否有任何新的問題需要注意。根據這些結果,我們收集了最新的法定預測,以了解分析師是否改變了盈利模式。
![1724544949901](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240825/42828558-0-76b1aaf002a1094b505e8f85a4fcbd36.webp/bigjpg)
Taking into account the latest results, the consensus forecast from 3SBio's eleven analysts is for revenues of CN¥8.81b in 2024. This reflects a credible 4.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 10% to CN¥0.78. In the lead-up to this report, the analysts had been modelling revenues of CN¥8.75b and earnings per share (EPS) of CN¥0.77 in 2024. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
考慮到最新業績,3sBio的11位分析師的共識預測是,2024年的收入爲88.1元人民幣。這反映了與過去12個月相比,收入的可信增長了4.6%。預計每股法定收益將增長10%,至0.78元人民幣。在本報告發布之前,分析師一直在模擬2024年的收入爲87.5元人民幣,每股收益(EPS)爲0.77元人民幣。因此,很明顯,儘管分析師已經更新了估計,但在最新業績公佈後,對該業務的預期沒有重大變化。
The analysts reconfirmed their price target of HK$8.06, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values 3SBio at HK$10.03 per share, while the most bearish prices it at HK$6.22. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
分析師再次確認了8.06港元的目標股價,這表明該業務表現良好,符合預期。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。目前,最看漲的分析師估值3sBio爲每股10.03港元,而最看跌的分析師估值爲6.22港元。如你所見,分析師對該股的未來並不完全一致,但估計範圍仍然相當狹窄,這可能表明結果並非完全不可預測。
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of 3SBio'shistorical trends, as the 9.4% annualised revenue growth to the end of 2024 is roughly in line with the 10% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 25% per year. So it's pretty clear that 3SBio is expected to grow slower than similar companies in the same industry.
我們可以從大局的角度看待這些估計值的另一種方式,例如預測如何與過去的表現相提並論,以及預測相對於業內其他公司是否或多或少看漲。我們可以從最新估計中推斷,預測預計3sBio的歷史趨勢將延續,因爲到2024年底的9.4%的年化收入增長與過去五年10%的年增長大致一致。相比之下,我們的數據表明,預計類似行業的其他公司(有分析師報道)的收入每年將增長25%。因此,很明顯,預計3sBio的增長速度將低於同一行業的同類公司。
The Bottom Line
底線
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that 3SBio's revenue is expected to perform worse than the wider industry. The consensus price target held steady at HK$8.06, with the latest estimates not enough to have an impact on their price targets.
要了解的最重要的一點是,市場情緒沒有重大變化,分析師再次確認該業務的表現符合他們先前的每股收益預期。幸運的是,分析師還重申了他們的收入預期,表明收入符合預期。儘管我們的數據確實表明,預計3sBio的收入表現將比整個行業差。共識目標股價穩定在8.06港元,最新估計不足以對其目標股價產生影響。
With that in mind, we wouldn't be too quick to come to a conclusion on 3SBio. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple 3SBio analysts - going out to 2026, and you can see them free on our platform here.
考慮到這一點,我們不會很快就3sBio得出結論。長期盈利能力比明年的利潤重要得多。根據多位3sBio分析師的估計,到2026年,你可以在我們的平台上免費查看。
However, before you get too enthused, we've discovered 1 warning sign for 3SBio that you should be aware of.
但是,在你變得太熱情之前,我們已經發現了3sBio的1個警告信號,你應該注意這一點。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。